Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 802-809

  Mocellin, Simone ^a   Pilati, Pierluigi ^a   Pian, Pierpaolo Da ^a   Forlin, Marco ^a   Corazzina, Susanna ^a   Rossi, Carlo Riccardo ^a   Innocente, Federico ^a   Ori, Carlo ^a   Casara, Dario ^a   Ujka, Francesca ^a   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Isolated hepatic perfusion; Liver metastasis; Locoregional treatment; Pharmacokinetics; Treatment personalization

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; LIVER PARENCHYMA; LIVER PERFUSION; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PLASMA; TREATMENT FAILURE; TUMOR REGRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEASIBILITY STUDIES; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; PILOT PROJECTS;

EID: 33846562484     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9108-7     Document Type: Article

References (27)

1. Lise M, Mocellin S, Pilati P, et al. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci 2005; 10:3042-57.
2. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001; 2:418-28.
3. Grover A, Alexander HR Jr. The past decade of experience with isolated hepatic perfusion. Oncologist 2004; 9:653-64.
4. Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16:35-53.
5. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
6. Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000; 5:416-24.
7. Lise M, Pilati P, Da Pian P, et al. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. J Chemother 2004; 16(Suppl 5):37-9.
8. Pilati P, Mocellin S, Rossi CR, et al. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function. World J Surg 2004; 28:775-81.
9. Casara D, Rubello D, Pilati P, et al. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nucl Med Commun 2004; 25:61-6.
10. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479-89.
11. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062-70.
12. de Wilt JH, van Etten B, Verhoef C, et al. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am 2004; 84:627-41.
13. Christoforidis D, Martinet O, Lejeune FJ, et al. Isolated liver perfusion for non-resectable liver tumours: a review. Eur J Surg Oncol 2002; 28:875-90.
14. Feldman ED, Wu PC, Beresneva T, et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 2004; 8:200-7.
15. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004; 40:1812-24.
16. Alexander HR Jr, Libutti SK, Bartlett DL, et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 2002; 95:730-6.
17. Lindner P, Fjalling M, Hafstrom L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 1999; 25:179-85.
18. Bartlett DL, Libutti SK, Figg WD, et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129:176-87.
19. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12:138-44.
20. Grover AC, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 2004; 136:1176-82.
21. Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004; 14:67-72.
22. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343-9.
23. Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90:1391-7.
24. de Vries MR, Rinkes IH, van de Velde CJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998; 147:107-19.
25. Vahrmeijer AL, van der Eb MM, Van Dierendonck JH, et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases?. Semin Surg Oncol 1998; 14:262-8.
26. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000; 82:1539-46.
27. Thompson JF, Eksborg S, Kam PC, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996; 6:267-71.